Departments of Cardiology (M.B.M., H.E.B., J.M.J., M.M., J.F.B., H.K., B.L.N.), Aarhus University Hospital, Denmark.
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD (M.B.M., O.D., M.J.B.).
Circulation. 2023 Apr 4;147(14):1053-1063. doi: 10.1161/CIRCULATIONAHA.122.061010. Epub 2023 Jan 9.
Low-density lipoprotein cholesterol (LDL-C) is an important causal risk factor for atherosclerotic cardiovascular disease (ASCVD). However, a sizable proportion of middle-aged individuals with elevated LDL-C level have not developed coronary atherosclerosis as assessed by coronary artery calcification (CAC). Whether presence of CAC modifies the association of LDL-C with ASCVD risk is unknown. We evaluated the association of LDL-C with future ASCVD events in patients with and without CAC.
The study included 23 132 consecutive symptomatic patients evaluated for coronary artery disease using coronary computed tomography angiography (CTA) from the Western Denmark Heart Registry, a seminational, multicenter-based registry with longitudinal registration of patient and procedure data. We assessed the association of LDL-C level obtained before CTA with ASCVD (myocardial infarction and ischemic stroke) events occurring during follow-up stratified by CAC>0 versus CAC=0 using Cox regression models adjusted for baseline characteristics. Outcomes were identified through linkage among national registries covering all hospitals in Denmark. We replicated our results in the -funded Multi-Ethnic Study of Atherosclerosis.
During a median follow-up of 4.3 years, 552 patients experienced a first ASCVD event. In the overall population, LDL-C (per 38.7 mg/dL increase) was associated with ASCVD events occurring during follow-up (adjusted hazard ratio [aHR], 1.14 [95% CI, 1.04-1.24]). When stratified by the presence or absence of baseline CAC, LDL-C was only associated with ASCVD in the 10 792/23 132 patients (47%) with CAC>0 (aHR, 1.18 [95% CI, 1.06-1.31]); no association was observed among the 12 340/23 132 patients (53%) with CAC=0 (aHR, 1.02 [95% CI, 0.87-1.18]). Similarly, a very high LDL-C level (193 mg/dL) versus LDL-C <116 mg/dL was associated with ASCVD in patients with CAC>0 (aHR, 2.42 [95% CI, 1.59-3.67]) but not in those without CAC (aHR, 0.92 [0.48-1.79]). In patients with CAC=0, diabetes, current smoking, and low high-density lipoprotein cholesterol levels were associated with future ASCVD events. The principal findings were replicated in the Multi-Ethnic Study of Atherosclerosis.
LDL-C appears to be almost exclusively associated with ASCVD events over ≈5 years of follow-up in middle-aged individuals with versus without evidence of coronary atherosclerosis. This information is valuable for individualized risk assessment among middle-aged people with or without coronary atherosclerosis.
低密度脂蛋白胆固醇(LDL-C)是动脉粥样硬化性心血管疾病(ASCVD)的一个重要的因果风险因素。然而,相当一部分 LDL-C 水平升高的中年患者,其冠状动脉钙化(CAC)评估并未发生冠状动脉粥样硬化。CAC 的存在是否改变了 LDL-C 与 ASCVD 风险的关联尚不清楚。我们评估了 CAC 存在或不存在的情况下,LDL-C 与 ASCVD 事件的相关性。
这项研究纳入了来自丹麦西部心脏注册中心(一个半国家、多中心的注册中心,纵向登记患者和程序数据)的 23132 例因冠状动脉疾病接受冠状动脉计算机断层扫描血管造影(CTA)评估的连续症状患者。我们使用 Cox 回归模型,根据 CAC>0 与 CAC=0,评估 CTA 前 LDL-C 水平与随访期间发生的 ASCVD(心肌梗死和缺血性卒中等)事件之间的关联,该模型调整了基线特征。结局通过丹麦所有医院的全国性注册中心的关联来确定。我们在由美国国立卫生研究院资助的多民族动脉粥样硬化研究中复制了我们的结果。
在中位随访 4.3 年期间,552 例患者发生了首次 ASCVD 事件。在整个人群中,LDL-C(每增加 38.7mg/dL)与随访期间发生的 ASCVD 事件相关(调整后的危险比[aHR],1.14[95%CI,1.04-1.24])。按基线 CAC 的存在或不存在进行分层时,仅在 CAC>0 的 10792/23132 例(47%)患者中,LDL-C 与 ASCVD 相关(aHR,1.18[95%CI,1.06-1.31]);在 CAC=0 的 12340/23132 例(53%)患者中,未观察到相关性(aHR,1.02[95%CI,0.87-1.18])。同样,极高的 LDL-C 水平(193mg/dL)与 LDL-C<116mg/dL 相比,与 CAC>0 的患者的 ASCVD 相关(aHR,2.42[95%CI,1.59-3.67]),但与 CAC=0 的患者无关(aHR,0.92[0.48-1.79])。在 CAC=0 的患者中,糖尿病、当前吸烟和低高密度脂蛋白胆固醇水平与未来 ASCVD 事件相关。在多民族动脉粥样硬化研究中复制了主要发现。
在伴有或不伴有冠状动脉粥样硬化证据的中年人群中,LDL-C 似乎与随访 ≈5 年内的 ASCVD 事件几乎完全相关。这些信息对于有或没有冠状动脉粥样硬化的中年人群进行个体化风险评估是有价值的。